Robert Rifkin, MD
Hematology & Oncology · Denver, CONPI 1134103476
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $199,033 of the $270,050 with a category attached, or 73.7%. 28 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 43.1% of the total. Reporting peaked in 2020 at $61,343 and has fallen 89.3% since, to $6,586 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $1267.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$116K
- Sanofi$38K
- Bristol Myers Squibb$17K
- Regeneron$17K
- Fresenius Kabi USA, LLC$14K
- Coherus Oncology, Inc.$13K
- plus $55K from 22 others
Across 1,283 payments — averaging $8605.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$6M
- Takeda Pharmaceuticals U.S.A., Inc.$1.2M
- GSK$860K
- E.r. Squibb & Sons, L.L.C.$766K
- Amgen$436K
- Bristol Myers Squibb$421K
- plus $1.4M from 9 others
What the payments were for
- Consulting fees$199,03374%
- Speaking & faculty fees$12,6755%
- Travel & lodging$51,93219%
- Food & beverage$5,1042%
- Education$6290%
- Gifts$6770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $116,402 |
| Sanofi | 23 | $38,018 |
| Bristol Myers Squibb | 15 | $17,085 |
| Regeneron | 11 | $16,683 |
| Fresenius Kabi USA, LLC | 13 | $14,173 |
| Coherus Oncology, Inc. | 14 | $12,895 |
| Amgen | 22 | $11,459 |
| GSK | 4 | $8,885 |
| Sandoz | 1 | $6,550 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,525 |
| Pfizer | 2 | $3,701 |
| Adaptive Biotechnologies Corporation | 18 | $3,686 |
| Karyopharm Therapeutics Inc. | 6 | $3,457 |
| Genmab U.S., Inc. | 9 | $3,280 |
| Janssen Global Services, LLC | 3 | $3,257 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,493 |
| Beigene USA, Inc. | 2 | $1,906 |
| Tosoh Bioscience, Inc. | 1 | $677 |
| Teva Pharmaceuticals USA, Inc. | 11 | $622 |
| Rigel Pharmaceuticals, Inc. | 1 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $48 |
| Mirati Therapeutics, Inc. | 3 | $47 |
| AbbVie | 2 | $34 |
| Secura Bio, Inc. | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $22 |
| Advanced Accelerator Applications | 1 | $18 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$270,050 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 53 | $680,171 |
| PomalystPomalidomide | 15 | $391,931 |
| ImbruvicaIbrutinib | 20 | $289,049 |
| RevlimidLenalidomide | 14 | $242,175 |
| BrukinsaZanubrutinib | 15 | $215,519 |
| SprycelDasatinib | 12 | $212,241 |
| TasignaNilotinib Hcl | 11 | $162,036 |
| EliquisApixaban | 63 | $63,662 |
| Deferiprone (3 Times A Day)Deferiprone | 13 | $63,504 |
| XareltoRivaroxaban | 60 | $50,608 |
| Posaconazole | 12 | $35,105 |
| Enoxaparin Sodium | 13 | $6,100 |
| Gabapentin | 20 | $2,694 |
| Acyclovir | 103 | $1,644 |
| Febuxostat | 12 | $1,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $4,525 | $604,17227 claims |
| Bristol Myers SquibbRevlimid | $17,085 | $242,17514 claims |
| Beigene USA, Inc.Brukinsa | $1,906 | $215,51915 claims |
| PfizerEliquis | $3,701 | $63,66263 claims |
| SandozEnoxaparin Sodium | $6,550 | $6,10013 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $622 | $1,644103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
- Marcello RottaDenver$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.